It showed 91.66% and 87.50% of serum and exosomal LDHC-positive cases, respectively, and 91.55% of LDH-C4–positive patients. LDHC/LDH-C4 exhibited high discrimination power in diagnosis, efficacy evaluation, relapse monitoring, and prognosis prediction for BC. Here, C4A is linked to breast cancer.